ArticleJournal of the American Chemical Society2011
Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection.
Article in Journal of the American Chemical Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 288 citations in OpenAlex.
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Novel Gold-Functionalization of Liposomes and Its Impact on Cellular Uptake and Trafficking.Molecular pharmaceutics · 2026Article
- Nanomedicine applications for the treatment of Staphylococcus aureus infections.FEMS microbiology reviews · 2026Review
- Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae.Drug delivery and translational research · 2025Article
- In Situ Application of Berberine-Loaded Liposomes on the Treatment of Osteomyelitis.ACS omega · 2025Article
- Synergistic Antibacterial Action of Norfloxacin-Encapsulated G4 Hydrogels: The Role of Boronic Acid and Cyclodextrin.Gels (Basel, Switzerland) · 2025Article
- Cholesterol-Rich Antibiotic-Loaded Liposomes as Efficient Antimicrobial Therapeutics.International journal of nanomedicine · 2025Article
- Toxin-triggered liposomes for the controlled release of antibiotics to treat infections associated with the gram-negative bacterium, Aggregatibacter actinomycetemcomitans.Colloids and surfaces. B, Biointerfaces · 2024Article
- Unleashing the promise of emerging nanomaterials as a sustainable platform to mitigate antimicrobial resistance.RSC advances · 2024Review
- Liposomal Rifabutin-A Promising Antibiotic Repurposing Strategy against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Current application and future perspectives of antimicrobial degradable bone substitutes for chronic osteomyelitis.Frontiers in bioengineering and biotechnology · 2024Review
- Metal Nanoparticles: Advanced and Promising Technology in Diabetic Wound Therapy.International journal of nanomedicine · 2024Review
- Recent advances in surface-mounted metal-organic framework thin film coatings for biomaterials and medical applications: a review.Biomaterials research · 2023Review
- Nanotechnology-A Light of Hope for Combating Antibiotic Resistance.Microorganisms · 2023Article
- Exploring Nanotechnology as a Strategy to Circumvent Antimicrobial Resistance in Bone and Joint Infections.ACS omega · 2023Review
- Synthesis of TiNanoscale advances · 2023Article
- Antibiotic-Loaded Gold Nanoparticles: A Nano-Arsenal against ESBL Producer-Resistant Pathogens.Pharmaceutics · 2023Review
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Precise antibacterial therapeutics based on stimuli-responsive nanomaterials.Frontiers in bioengineering and biotechnology · 2023Review
- Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We report a new approach to selectively deliver antimicrobials to the sites of bacterial infections by utilizing bacterial toxins to activate drug release from gold nanoparticle-stabilized phospholipid liposomes. The binding of chitosan-modified gold nanoparticles to the surface of liposomes can effectively prevent them from fusing with one another and from undesirable payload release in regular storage or physiological environments. However, once these protected liposomes "see" bacteria that secrete toxins, the toxins will insert into the liposome membranes and form pores, through which the encapsulated therapeutic agents are released. The released drugs subsequently impose antimicrobial effects on the toxin-secreting bacteria. Using methicillin-resistant Staphylococcus aureus (MRSA) as a model bacterium and vancomycin as a model anti-MRSA antibiotic, we demonstrate that the synthesized gold nanoparticle-stabilized liposomes can completely release the encapsulated vancomycin within 24 h in the presence of MRSA bacteria and lead to inhibition of MRSA growth as effective as an equal amount of vancomycin-loaded liposomes (without nanoparticle stabilizers) and free vancomycin. This bacterial toxin enabled drug release from nanoparticle-stabilized liposomes provides a new, safe, and effective approach for the treatment of bacterial infections. This technique can be broadly applied to treat a variety of infections caused by bacteria that secrete pore-forming toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.